Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
about
Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?Clinical effectiveness of dolutegravir in the treatment of HIV/AIDSDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceHIV and Zika: When will we be able to end these epidemics?Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsProfile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to dateEfavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsActive targeted drug delivery for microbes using nano-carriersEfavirenz and the CNS: what we already know and questions that need to be answeredDolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and reviewCellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyAn Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial TherapyWhat's new for antiretroviral treatment in women with HIVProjected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.HIV integrase inhibitors: a new era in the treatment of HIV.Dolutegravir: clinical efficacy and role in HIV therapy.Novel approaches to HIV therapy.Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsDolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studySingle-Tablet Regimens in HIV TherapyResistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance ProfileHIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integraseDolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionManagement of HIV infection in patients with cancer receiving chemotherapy.Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.What if HIV were unable to develop resistance against a new therapeutic agent?Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management.Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.The role of dolutegravir in the management of HIV infectionSimian-tropic HIV as a model to study drug resistance against integrase inhibitors.Antiretroviral therapy: when to start
P2860
Q26765043-78BE4125-EAEE-4709-A357-4E5C9FFD2128Q26778450-7DB51C00-0418-4394-83AC-9C7D30A3F7CAQ26799712-0AB9240B-4910-4803-B562-184B374B9A6AQ26801286-6BD10F80-8211-4C1D-8CC2-C7F46B6BFAB7Q27927993-498DE220-9A36-48E6-8BBF-4A1F9ECBD3D5Q28069383-62F93E8C-4BCB-4A86-B687-9BD9CA74A63FQ28079025-CAC63D4F-F99C-4583-AA0D-F39D48D65F64Q28081266-6DFA63AE-9E4F-4296-879B-1B5BBCC5CECAQ28082463-12428E3D-CABD-4DD5-9992-6B3E13A23947Q28085028-8113FF77-20EA-4CC8-BECE-D0A61C4C6086Q28086985-26A197EE-D7FC-4B49-B3AE-83003E52CE1DQ28551873-D63DF6ED-5730-4B88-979F-DD4A0C826F6AQ28552210-DDDDA289-86DE-48A1-AA3B-40ECEB9E5801Q30391322-6C510FD4-6324-4E94-A387-24397ED93E84Q30394059-B1292A22-8401-483F-9E36-DAD24B143B87Q30956943-27D3F9CA-D8FF-43E5-A075-940F9B9B4494Q33725024-D000F5C4-9590-4751-8372-AC9699AA8B61Q33777819-9BFEC01F-54EE-45A2-B69B-37EE78273C2AQ33878754-427FE970-071D-45C8-BE32-D93C28A32F75Q33880221-177A9150-D698-4D32-8EAE-504B1E9F0279Q33939110-440AAFA5-2BD5-4FDC-AF57-95001BDE7134Q33963458-748E9D27-909A-4531-A8DA-B04DFCAA7D9BQ34102246-550E5F79-4B3E-402F-9E16-01742C126894Q34134900-C6088D86-977A-4C33-9DB2-C079C0DC8AB4Q34202181-B8489A3C-9FF7-44FB-A5F1-B73A399821F4Q34536677-5CC64F2A-047E-46F3-A1FB-B70FB92B6E71Q34540677-6FC63646-4B65-4CB2-B287-4CBC076B1FB3Q34597650-53D10017-998B-48F6-A3FB-37C77DCBEA05Q34726183-57AAC3B3-501E-44B5-8C5F-51346621F452Q34736194-0F8376D5-A285-4F67-8B64-7392284138D5Q34823275-5087261A-F30C-4C94-983E-9792E6C57D7AQ34976284-1BBCB70B-0046-40FA-9014-EE58DD36AF62Q35008342-1A937A24-C237-4D53-B829-FEA65410EDB3Q35021555-9DAFF71B-8C93-4511-B1C8-E83B83E3BE5CQ35051393-560EA1F6-0B84-4641-8D54-E58E1CFC76F4Q35094201-ABC1F380-6884-41E7-B4FC-FBFE7A689683Q35103606-266282B7-B511-4001-9566-83CF01DF390DQ35121450-96D03C91-6989-4420-85E6-BB462E20FF07Q35169003-6534A176-0352-423B-AA93-F66A99F13C25Q35204279-EC3D10AE-A7A9-44C6-A149-07629391D8CA
P2860
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
@en
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
@nl
type
label
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
@en
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
@nl
prefLabel
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
@en
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
@nl
P2093
P356
P1476
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
@en
P2093
Andrea Eberhard
Antonio Antela
Brian Wynne
Catherine Granier
Dan Duiculescu
Felix Gutiérrez
Franco Maggiolo
Garrett Nichols
Keith Pappa
Laurent Hocqueloux
P304
P356
10.1056/NEJMOA1215541
P407
P577
2013-11-01T00:00:00Z